Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8100MR)

This product GTTS-WQ8100MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8100MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ280MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ5708MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ7217MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ5223MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ3124MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ7776MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ8705MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ3456MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AZD8895
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW